China ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis

China ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Analysis


$ 3999

China's Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market is projected to grow from $2.37 Bn in 2022 to $4.73 Bn in 2030 with a CAGR of 9% for the year 2022-30. A more significant proportion of the young population and therefore an increasing prevalence of ADHD among children in China are driving the growth of the market. The China ADHD therapeutics market is segmented by drug, drug type, demographics, and by distribution channel. Shanghai Fosun Pharmaceutical, Huadong Medicine, and Adlon Therapeutics are the key players in the market.

ID: IN10CNPH028 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Parul Choudhary

Buy Now

China Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Executive Analysis

The China Attention Deficit Hyperactivity Disorder (ADHD) therapeutics market size is at around $2.37 Bn in 2022 and is projected to reach $4.73 Bn in 2030, exhibiting a CAGR of 9% during the forecast period. According to the South China Morning Post's most recent healthcare report, China's combined pharmaceutical and biopharma R&D expenditure will increase at a compound annual rate of 23% until 2023, reaching $49 Bn. By then, 23% of the global total for drug finding and testing will be spent on pharmaceutical and biopharma R&D in China. Before 2030, the SCMP research found that China could be on par with America and Europe in terms of its ability to produce best-in-class medications. $10 Bn of all exports in Q1 were made up of medical supplies from China, which also produces 40% of the Application programming interface (API) used globally. China is the second-largest market in the globe for healthcare with a spending of $3.5 Tn.

One of the most prevalent juvenile psychiatric conditions is Attention Deficit Hyperactivity Disorder (ADHD), which manifests as impulsivity, hyperactivity, and inattention. As a significant public health issue, ADHD has been linked to a broad range of negative health outcomes for those who are affected. The world's largest population of children and teenagers is found in China and 5.7% of Chinese children and teenagers have ADHD. Chinese children may experience chronic stress as a result of their country's highly competitive educational system and mounting scholastic pressures, making them more vulnerable to mental health issues like ADHD. According to government figures, over 90% of childhood, ADHD cases in China still go undiagnosed. Only one-third of children who are diagnosed even go on to receive medication or behavioral treatment.

In China, drug therapy can be considered after thoroughly discussing the benefits and drawbacks of drug use with parents. For patients who are of school-age, drug therapy, behavioral therapy, or a combination of both is favored. Medication is still favored for patients whose bodily functions are affected after adulthood (age 18). Cognitive behavioral therapy, however, may be an option if a patient refuses medication, the medication is ineffective, or the medication has unacceptably high side effects.

In China, Traditional Chinese treatment (TCM) is a widely accepted and accepted complement to Western treatment. The Liver and Kidneys are the primary organs where Liver-Kidney Yin imbalance manifests itself in ADHD, according to TCM. It's conceivable that ADHD has a genetic component because, according to TCM, your constitution is built on the kidney. Typically, a child's Yin is inadequate; without enough Yin, there is not enough Yang to maintain equilibrium. Consequently, there is a higher chance of having a Liver-Kidney Yin deficit. TCM therapy for ADHD typically uses Chinese herbs, medications, and/or acupuncture to balance the Yin and Yang of the five Organs. Typically, the healing process is prolonged and complicated.

china attention deficit hyperactivity disorder therapeutics market

Market Dynamics

Market Growth Drivers

Since there are many young people in China, there is a sizable prospective market for the treatment of ADHD. Patients and their families are seeking therapy for the condition as they become more aware of it, which is helping the China ADHD therapeutics market to expand. The Chinese government is offering more assistance and resources for the identification and therapy of ADHD, which is assisting in the market's expansion. The availability of advanced therapies, such as non-stimulant medications and behavioral therapies, is encouraging the development of the ADHD market in China.

Market Restraints

In China, there is a stigma associated with mental health conditions, including ADHD, and misunderstandings of the disease may result in neglectful treatment. A further issue is a general opposition to giving children medicines in China. The traditional Chinese view that all drugs are somewhat harmful to the body is one that many families cling to as major restraint to the growth of China's ADHD therapeutics market.

Competitive Landscape

Key Players

  • Jiangsu Hengrui Medicine (CHN)
  • BeiGene (CHN)
  • Chongqing Zhifei Biological Products (CHN)
  • Shanghai Fosun Pharmaceutical (CHN)
  • Huadong Medicine (CHN)
  • Adlon Therapeutics
  • Amnel Pharmaceuticals
  • Aytu Biopharma
  • American Brivision
  • Cingulate
  • Eli Lilly
  • GSK

Healthcare Policies and Regulatory Landscape

The National Medical Products Administration (NMPA), formerly the China Food and Drug Administration (CFDA), which answers to the State Administration of Market Regulation (SAMR), is responsible for regulating drugs and medical products. The NMPA is in charge of carrying out drug registration and approvals, giving advice to provincial authorities, and collaborating with provincial investigators to assign clinical trial facility inspections and foreign inspections. The classification of the drug product in accordance with NMPA regulations determines the licensing process for pharmaceuticals in China. In China, the classification determines the regulatory clearance procedure. To complete the registration procedure with the National Medical Products Administration, a foreign manufacturer or applicant must have a legally designated local agent in China who is in charge of pharmaceutical regulatory matters. The NMPA must receive the applicant's Marketing Authorization Holding (MAH) registration. According to NMPA regulations, the MAH must submit an application for the renewal certificate six months before the Drug Approval License's five-year validity term is through.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

ADHD (Attention Deficit Hyperactivity Disorder) Therapeutic Market Segmentation

By Drug Type (Revenue, USD Billion):

  • Stimulants
    • Amphetamine
    • Methylphenidate
    • Dextroamphetamine
    • Dexmethylphenidate
    • Lisdexamfetamine
    • Others
       
  • Non-Stimulants
    • Atomoxetine
    • Bupropion
    • Guanfacine
    • Clonidine

By Age Group (Revenue, USD Billion):

  • Pediatric And Adolescent
  • Adult

By Distribution Channel (Revenue, USD Billion):

  • Hospital Pharmacies
  • Speciality Clinics
  • Retail Pharmacies
  • e-Commerce

By Psychotherapy (Revenue, USD Billion):

  • Behaviour Therapy
  • Cognitive Behavioral Therapy
  • Interpersonal Psychotherapy
  • Family Therapy

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 03 August 2024
Updated by: Riya Doshi

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up